DiaMedica Therapeutics SVP Julie VanOrsdel Daves resigns; Rebekah de Vitry Fries assumes clinical operations leadership

DiaMedica Therapeutics Inc.

Julie VanOrsdel Daves resigns as SVP, Clinical Development Operations effective April 18, 2024 for personal reasons.
Rebekah de Vitry Fries, current VP of Clinical Operations, will assume leadership of clinical operations.
De Vitry Fries joined DiaMedica as a consultant on Jan 3, 2024 and became full-time employee on Feb 20, 2024.
She previously served as Head of Clinical Operations at Epygenix Therapeutics, reporting to same CMO Lorianne Musuoka.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Julie VanOrsdel Daves

Senior Vice President, Clinical Development Operations

DMAC · DiaMedica Therapeutics Inc.

Effective: 2024-04-18
Successor: Rebekah de Vitry Fries
Filed: April 10, 2024, 7:59 PM ET

Julie VanOrsdel Daves MSHS, CCRP notified us of her resignation as Senior Vice President, Clinical Development Operations of DiaMedica Therapeutics Inc. (“DiaMedica”), effective as of April 18, 2024, for personal reasons.

Role change

Rebekah de Vitry Fries

Other Named Officer

DMAC · DiaMedica Therapeutics Inc.

Effective: 2024-04-18
Filed: April 10, 2024, 7:59 PM ET

Following the departure of Ms. Daves, Rebekah de Vitry Fries, who currently serves as DiaMedica’s Vice President of Clinical Operations, will assume leadership of DiaMedica’s clinical operations.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Julie VanOrsdel Daves resigned as Senior Vice President, Clinical Development Operations at DiaMedica Therapeutics Inc..

Action: resigned
Role: Senior Vice President, Clinical Development Operations

Exact text from the filing

Julie VanOrsdel Daves MSHS, CCRP notified us of her resignation as Senior Vice President, Clinical Development Operations of DiaMedica Therapeutics Inc. (“DiaMedica”), effective as of April 18, 2024, for personal reasons.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.9

Rebekah de Vitry Fries changed role as other_named_officer at DiaMedica Therapeutics Inc..

Action: assumed leadership of clinical operations

Exact text from the filing

Following the departure of Ms. Daves, Rebekah de Vitry Fries, who currently serves as DiaMedica’s Vice President of Clinical Operations, will assume leadership of DiaMedica’s clinical operations.

View on SEC.gov

DiaMedica Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001437749-24-011645

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.